Intraoperative & Critical Care
Scalp EEG Flags Treatable NCSE in Severe COVID-19 Encephalopathy
A case report in Clinical EEG and Neuroscience shows early scalp EEG uncovered treatable non-convulsive status epilepticus behind unexplained coma in severe COVID-19 encephalopathy.
Updated
A case report published ahead of print in Clinical EEG and Neuroscience documents that scalp EEG identified non-convulsive status epilepticus (NCSE) — continuous seizure activity on the recording without visible convulsions — as a treatable cause of persistently depressed consciousness in a patient with severe COVID-19-associated encephalopathy. The finding matters because clinicians on intensive-care units routinely attribute unresponsiveness in these patients to hypoxemia, systemic inflammation, sedatives, or metabolic derangement, and may never order an EEG at all.
Why does this case change bedside reasoning?
The authors frame the problem bluntly. Persistent depressed consciousness in severe coronavirus disease 2019, they note, is commonly attributed to four mechanisms: hypoxemia (low blood oxygen), systemic inflammation, sedative exposure, and metabolic disturbance. Non-convulsive status epilepticus sits outside that default differential, yet it is the one cause on the list that antiseizure therapy can directly reverse.
By capturing the diagnostic EEG early, the treating team converted an assumption — that the patient was simply encephalopathic and unduly sedated — into an electrophysiologically confirmed diagnosis. The case report does not claim a novel syndrome. It demonstrates concretely that early scalp EEG in the right clinical setting can uncover ongoing seizure activity that standard ICU workup would have missed.
What should monitoring units take from it?
For reading rooms and epilepsy monitoring practice, the report carries a straightforward implication: when a severe COVID-19 patient remains unresponsive beyond what sedation weaning and metabolic correction predict, request an EEG rather than extending the attribution to vague encephalopathy. Scalp EEG, the modality used here, is non-invasive and available at the bedside in most tertiary units.
The diagnostic stakes are not trivial. NCSE left untreated prolongs impaired consciousness and carries its own morbidity, whereas treatment — antiseizure medication guided by the electrographic findings — can restore responsiveness. The report positions EEG not as a research tool but as a triage instrument for a treatable, silent cause of coma-level unresponsiveness.
How firm are the claims?
Readers should weigh the evidence for what it is. This is a single case report, ahead of print, not a cohort study. It establishes that NCSE can masquerade as COVID-19 encephalopathy in at least one documented patient and that early scalp EEG caught it. It does not estimate how often NCSE underlies COVID-19-associated encephalopathy across populations, and no prevalence figure appears in the report.
The study is human clinical data, wholly — no animal work, no investigational device, and no brain-computer interface claim anywhere in it. The recording method named is standard clinical EEG, reported in the journal Clinical EEG and Neuroscience, a peer-reviewed venue for exactly this kind of neurophysiological observation.
What comes next?
The natural extension, and the direction the report invites, is systematic early EEG screening of encephalopathic COVID-19 cohorts to establish how many harbor non-convulsive status epilepticus — and how many recover consciousness once it is treated.
Based on
Source: Clinical EEG and Neuroscience (SAGE).
Priya Raman
Show full bio
Market editor covering regulation, policy and their impact on Clinical neurophysiology and EEG interpretation at EEG Signal.